Press Release

Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended…

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor…

Calidi Biotherapeutics announced a new patent for its SuperNova technology, advancing its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox…

Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today announced that its Board of Directors has approved the…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) has appointed Dr. George E. Peoples, MD, FACS, to the company’s Board of Directors, effective July 1, 2024. Calidi is a clinical-stage…

The exclusive event, hosted by RedChip Companies, will feature Calidi Biotherapeutics Chief Business Officer Stephen Thesing and Chief Financial Officer Andrew Jackson, who will share insight into the Company’s proprietary…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that it entered into a collaboration agreement with…

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of three abstracts in a poster session during…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has entered a definitive agreement for the immediate exercise of Series B and C warrants, expected to generate approximately $2.1…

Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting Presented new data on the mechanisms of…

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of three abstracts that will be presented in…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of…

Calidi Biotherapeutics announces a public offering to raise $6.1 million closing by April 18, 2024.

Data supports CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor virotherapies designed improve antitumor activity in the clinic.

City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic ovarian cancer using Calidi’s licensed lead asset, CLD-101. The grant highlights CIRM’s continued support of…

– Preclinical models have demonstrated the ability to resist oncolytic virus inactivation by human serum and target diverse tumor types– Novel therapeutic approach allows for ease of administration, increased cost-effectiveness,…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced three presentations on Calidi’s NeuroNova (NNV) and SuperNova (SNV)…

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company’s Board…